Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478513 | 0.94 | KMT2A (0.51) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11480079 | 0.94 | KMT2A (0.51) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11479875 | 0.94 | KMT2A (0.51) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11479955 | 0.94 | KMT2A (0.50) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11473112 | 0.92 | KMT2A (0.49) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11481999 | 0.92 | KMT2A (0.49) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11471027 | 0.92 | KMT2A (0.49) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11470898 | 0.87 | KMT2A (0.61) | KMT2ATSHRMEN1ALDH1A1RAB9A | |
| SCHEMBL11480989 | 0.82 | TSHR (0.47) | KMT2ATSHRHTTPIK3CDMEN1 | |
| SCHEMBL11470310 | 0.81 | KMT2A (0.81) | KMT2ATSHRMEN1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107753481-A | A kind of western smooth class pharmaceutical composition containing buffer | 沈阳药科大学 | 2018-03-06 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4216221-A | MNEMIC PROCESSES | U C B, SOCIETE ANONYME (BE) | 1980-08-05 | — | — | US | claimed |
| EP-3890833-B1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047548-A1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220047587-A1 | SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3890833-A1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE IN A NON-RACEMIC RATIO | Metys Pharmaceuticals AG (CH) | 2021-10-13 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-4216221-A | MNEMIC PROCESSES | U C B, SOCIETE ANONYME (BE) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047587-A1 | SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO | CNR2, SCN2A, SIGMAR1 | KMT2A 4000/4885TSHR 3137/4885HTT 267/4885 |
| US-20220047548-A1 | SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO | GAP43, CACNA1E, CACNA1D | KMT2A 4352/4885TSHR 4755/4885HTT 1423/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | KMT2A 4411/4885TSHR 1871/4885HTT 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.